US Cardiac Troponin Diagnostics Market, Forecast to 2021

US Cardiac Troponin Diagnostics Market, Forecast to 2021

High Prevalence of Heart Disease Propels Market Growth

RELEASE DATE
08-Jun-2018
REGION
North America
Research Code: P9AF-01-00-00-00
SKU: HC03024-NA-MR_22001

$4,950.00

Special Price $3,712.50 save 25 %

In stock
SKU
HC03024-NA-MR_22001

$4,950.00

$3,712.50 save 25 %

DownloadLink

Pay by invoice

ENQUIRE NOW

Description

Cardiac troponins help to diagnose nearly two-thirds of the patients in the diagnosis Acute Coronary Syndrome (ACS) who are missed out by Echocardiogram (ECG). ECG can detect only one-third of the patients with persistent ST-segment Elevation (STEMI), whereas cardiac troponins can distinguish patients without ST-segment elevation (NSTEACS; non-ST segment elevation ACS) who require a conservative Unstable Angina (UA) or early-invasive approach (NSTEMI).

In addition to significant pricing challenges, there is growing competition encouraged by the adoption of point-of-care devices at physician offices and hospitals. Although technicians and patients prefer point-of-care devices, physicians and hospitals are still slow in adopting these devices due to conventional mindset and cost. High-sensitivity troponins are the latest addition to troponin tests and have expanded the clinical application. With the recent Food and Drug Administration (FDA) approval of a high-sensitivity troponin assay from Roche, it is soon expected that many more competitors will try to secure FDA approval that will further intensify the competition.

In the US, troponin I and T faced a decline similar to other tests due to reimbursement cuts. However, the volume of tests used for troponin T has been increasing and will continue to do so for the next 5 years. Due to the implementation of the ACA, reimbursement cuts have resulted in increased pricing pressure on many of these lab tests. This is expected to continue for the next 5 years if the same systems are going to be used to reimburse tests. The Protecting Access to Medicare Act (PAMA) regulation is expected to impact the price of routine tests. This downward trend in pricing would impact manufacturers’ ability to be paid at the same rate for the cost of reagents.

Research Scope

The objective of this research is to establish an understanding of the market for cardiac biomarker Troponin used for the diagnosis of acute myocardial infarction. The research covers the revenue generated by the use of cardiac troponin tests for diagnosis of acute myocardial infarction.


Key Issues Addressed

  • What are the key healthcare trends that could impact the global cardiac biomarker diagnostics market?
  • What are the market drivers and restraints that are impacting market growth?
  • What are the unmet needs and opportunities for existing and emerging participants?
  • What are the segment shares of key market participants?
  • How are companies dealing with the challenges in the market space?
  • What are the future trends and how is the forecast scenario of Acute Myocardial infarction (AMI) biomarkers diagnostics in different regions?

RESEARCH: INFOGRAPHIC

This infographic presents a brief overview of the research, and highlights the key topics discussed in it.
Click image to view it in full size

Table of Contents

Global Cardiac Troponin Market—Executive Summary

US Cardiac Troponins Market—Executive Summary

Western European Cardiac Troponins Market—Executive Summary

APAC Cardiac Troponins Market—Executive Summary

Scope and Segmentation

Market Engineering Measurements

Cardiac Diagnostics Industry Overview

Cardiac Biomarkers Diagnostics Overview

Executive Summary—3 Big Predictions

Market Engineering Measurements

Forecast Methodology

Revenue Forecast

Percent Revenue Breakdown by Segment—Lab-based Tests Versus POCT

Revenue Forecast by Segment

Percent Revenue Forecast by Region

Revenue Forecast by Region

Percent of Revenue by Region

Market Share

Market Share Analysis

Top Competitors

Market Engineering Measurements

Revenue Forecast

Segment Share

Segment Share Analysis

Market Engineering Measurements

Revenue Forecast

Segment Share

Segment Share Analysis

Executive Summary

Scope and Segmentation

Market Engineering Measurements

CEO’s Perspective

Key Companies to Watch

Market Background

Market Background—Prevalence Rate

Market Overview—Testing Procedure

Current Trends in US Troponin Market

Troponin Testing Locations

New Market Opportunities

Competitive Structures

Product Portfolio

Market Drivers

Market Restraints

Key Findings

Forecast Methodology

Market Engineering Measurements

Revenue Forecast

Segment Breakdown

Revenue Forecast by Segment

US Lab-based Test Segment—Pricing Trends and Forecast

Market Share

Market Share Analysis

Major Growth Opportunities

Growth Opportunity Matrix—Key Opportunities and Impact on Businesses

Growth Opportunity 1—Companion Diagnostics

Growth Opportunity 2—POCT in Cardiac Biomarker Diagnostics

Growth Opportunity 3—Integrated and Efficient System

Growth Opportunity 4—Digital Health and Diagnostics Inter- convergence Model

Strategic Imperatives for Success and Growth

Key Findings

Market Engineering Measurements

Revenue Forecast

Market Share

Market Share Analysis

Key Findings

Market Engineering Measurements

Revenue Forecast

Market Share

Market Share Analysis

The Last Word—3 Big Predictions

Legal Disclaimer

Market Engineering Methodology

List of Other Companies in Biomarkers Research, Development, and/or Services

List of Exhibits

List of Figures
  • 1. Total Cardiac Troponin Diagnostics Market: Market Engineering Measurements, Global, 2016
  • 2. Total Cardiac Troponin Diagnostics Market: Revenue Forecast by Region, Global, 2015–2021
  • 3. Total Cardiac Troponin Diagnostics Market: Company Market Share Analysis of Top 5 Market Participants, Global, 2016
  • 4. Total Cardiac Troponin Diagnostics Market: SWOT Analysis, Global, 2016
  • 5. Lab-based Tests Segment: Market Engineering Measurements, Global, 2016
  • 6. Lab-based Tests Segment: Company Segment Share Analysis of Top 4 Participants, Global, 2016
  • 7. POCT Segment: Market Engineering Measurements, Global, 2016
  • 8. POCT Segment: Company Segment Share Analysis of Top 4 Participants, Global, 2016
  • 9. Cardiac Troponin Diagnostics Market: New Market Opportunities, US, 2016
  • 10. Cardiac Troponin Diagnostics Market: Competitive Structure, US, 2016
  • 11. Cardiac Troponin Diagnostics Market: Product Analysis, US, 2016
  • 12. Cardiac Troponin Diagnostics Market: Key Market Drivers, US, 2017–2021
  • 13. Cardiac Troponin Diagnostics Market: Key Market Restraints, US, 2017–2021
  • 14. Cardiac Troponin Diagnostics Market: Market Engineering Measurements, US, 2016
  • 15. Cardiac Troponin Diagnostics Market: Company Market Share Analysis of Top 7 Participants, US, 2016
  • 16. Cardiac Troponin Diagnostics Market: Growth Opportunity Matrix, US, 2016
  • 17. Lab-based Tests Segment: Market Engineering Measurements, US, 2016
  • 18. Lab-based Tests Segment: Company Market Share Analysis of Top 4 Participants, US, 2016
  • 19. POCT Segment: Market Engineering Measurements, US, 2016
  • 20. POCT Segment: Company Market Share Analysis of Top 6 Participants, US, 2016
List of Charts
  • 1. Total Cardiac Troponin Diagnostics Market: Market Engineering Measurements, Global, 2016
  • 2. Total Cardiac Troponin Diagnostics Market: Industry Overview, Global, 2016
  • 3. Total Cardiac Troponin Diagnostics Market: Market Overview, Global, 2016
  • 4. Total Cardiac Troponin Diagnostics Market: Revenue Forecast, Global, 2015–2021
  • 5. Total Cardiac Troponins Market: Percent Revenue by Segment, Global, 2016
  • 6. Total Cardiac Troponins Market: Percent Revenue Forecast by Segment, Global, 2021
  • 7. Total Cardiac Troponin Diagnostics Market: Revenue Forecast by Segment, Global, 2015–2021
  • 8. Total Cardiac Troponin Diagnostics Market: Percent Revenue Forecast by Region, Global, 2015–2021
  • 9. Total Cardiac Troponin Diagnostics Market: Percent of Revenue by Region, Global, 2016
  • 10. Cardiac Troponin Lab-based Test Segment: Percent of Revenue by Region, Global, 2016
  • 11. Cardiac Troponin POCT Segment: Percent of Revenue by Region, Global, 2016
  • 12. Total Cardiac Troponin Diagnostics Market: Percent Revenue Breakdown, Global, 2016
  • 13. Lab-based Tests Segment: Revenue Forecast, Global, 2015–2021
  • 14. Lab-based Tests Segment: Percent Revenue Breakdown, Global, 2016
  • 15. POCT Segment: Revenue Forecast, Global, 2015–2021
  • 16. POCT Segment: Percent Revenue Breakdown, Global, 2016
  • 17. Cardiac Troponin Diagnostics Market: Market Engineering Measurements, US, 2016
  • 18. Cardiac Troponin Diagnostics Market: Prevalence Rate, US, 2009–2020
  • 19. Laboratory Based Tests Segment: Testing Locations, US, 2016
  • 20. POCT Based Tests Segment: Testing Locations, US, 2016
  • 21. Cardiac Troponin Diagnostics Market: Percent Revenue Breakdown by Region, US, 2016
  • 22. Cardiac Troponin Diagnostics Market: Revenue Forecast, US, 2015–2021
  • 23. Cardiac Troponin Diagnostics Market: Market Segmentation, US, 2016
  • 24. Cardiac Troponin Diagnostics Market: Market Segmentation Forecast, US, 2021
  • 25. Cardiac Troponin Diagnostics Market: Revenue Forecast by Segment, US, 2015–2021
  • 26. Lab-based Test Segment: Average Price for Lab-based Tests, US, 2015–2021
  • 27. Cardiac Troponin Diagnostics Market: Percent Revenue Breakdown, US, 2016
  • 28. Cardiac Troponin Diagnostics Market: Percent Revenue Breakdown by Segment, US, 2016
  • 29. Lab-based Tests Segment: Revenue Forecast, US, 2015–2021
  • 30. Lab-based Tests Segment: Percent Revenue Breakdown, US, 2016
  • 31. Cardiac Troponin Diagnostics Market: Percent Revenue Breakdown by Segment, US, 2016
  • 32. POCT Segment: Revenue Forecast, US, 2015–2021
  • 33. POCT Segment: Percent Revenue Breakdown, US, 2016
Related Research
Cardiac troponins help to diagnose nearly two-thirds of the patients in the diagnosis Acute Coronary Syndrome (ACS) who are missed out by Echocardiogram (ECG). ECG can detect only one-third of the patients with persistent ST-segment Elevation (STEMI), whereas cardiac troponins can distinguish patients without ST-segment elevation (NSTEACS; non-ST segment elevation ACS) who require a conservative Unstable Angina (UA) or early-invasive approach (NSTEMI). In addition to significant pricing challenges, there is growing competition encouraged by the adoption of point-of-care devices at physician offices and hospitals. Although technicians and patients prefer point-of-care devices, physicians and hospitals are still slow in adopting these devices due to conventional mindset and cost. High-sensitivity troponins are the latest addition to troponin tests and have expanded the clinical application. With the recent Food and Drug Administration (FDA) approval of a high-sensitivity troponin assay from Roche, it is soon expected that many more competitors will try to secure FDA approval that will further intensify the competition. In the US, troponin I and T faced a decline similar to other tests due to reimbursement cuts. However, the volume of tests used for troponin T has been increasing and will continue to do so for the next 5 years. Due to the implementation of the ACA, reimbursement cuts have resulted in increased pricing pressure on many of these lab tests. This is expected to continue for the next 5 years if the same systems are going to be used to reimburse tests. The Protecting Access to Medicare Act (PAMA) regulation is expected to impact the price of routine tests. This downward trend in pricing would impact manufacturers’ ability to be paid at the same rate for the cost of reagents.--BEGIN PROMO--

Research Scope

The objective of this research is to establish an understanding of the market for cardiac biomarker Troponin used for the diagn

More Information
No Index No
Podcast No
Table of Contents | Executive Summary~ || Global Cardiac Troponin Market—Executive Summary~ || US Cardiac Troponins Market—Executive Summary~ || Western European Cardiac Troponins Market—Executive Summary~ || APAC Cardiac Troponins Market—Executive Summary~ || Scope and Segmentation~ || Market Engineering Measurements~ || Cardiac Diagnostics Industry Overview~ || Cardiac Biomarkers Diagnostics Overview~ || Executive Summary—3 Big Predictions~ | Forecasts and Discussion~ || Market Engineering Measurements~ || Forecast Methodology~ || Revenue Forecast~ || Percent Revenue Breakdown by Segment—Lab-based Tests Versus POCT~ || Revenue Forecast by Segment~ || Percent Revenue Forecast by Region~ || Revenue Forecast by Region~ || Percent of Revenue by Region~ | Competitive Environment~ || Market Share~ || Market Share Analysis~ || Top Competitors~ | Lab-based Tests Segment Analysis~ || Market Engineering Measurements~ || Revenue Forecast~ || Segment Share~ || Segment Share Analysis~ | POCT Segment Analysis~ || Market Engineering Measurements~ || Revenue Forecast~ || Segment Share~ || Segment Share Analysis~ | Regional Analysis—US~ || Executive Summary~ || Scope and Segmentation~ || Market Engineering Measurements~ || CEO’s Perspective~ || Key Companies to Watch~ | Market Overview~ || Market Background~ || Market Background—Prevalence Rate~ || Market Overview—Testing Procedure~ || Current Trends in US Troponin Market~ || Troponin Testing Locations~ | Competitive Playbook~ || New Market Opportunities~ || Competitive Structures~ || Product Portfolio~ | Drivers and Restraints~ || Market Drivers~ || Market Restraints~ | Forecasts and Discussion~ || Key Findings~ || Forecast Methodology~ || Market Engineering Measurements~ || Revenue Forecast~ || Segment Breakdown~ || Revenue Forecast by Segment~ || US Lab-based Test Segment—Pricing Trends and Forecast~ | Competitive Environment~ || Market Share~ || Market Share Analysis~ | Growth Opportunity~ || Major Growth Opportunities~ || Growth Opportunity Matrix—Key Opportunities and Impact on Businesses~ || Growth Opportunity 1—Companion Diagnostics~ || Growth Opportunity 2—POCT in Cardiac Biomarker Diagnostics~ || Growth Opportunity 3—Integrated and Efficient System~ || Growth Opportunity 4—Digital Health and Diagnostics Inter- convergence Model~ || Strategic Imperatives for Success and Growth~ | Lab-based Segment Analysis~ || Key Findings~ || Market Engineering Measurements~ || Revenue Forecast~ || Market Share~ || Market Share Analysis~ | POCT Segment Analysis~ || Key Findings~ || Market Engineering Measurements~ || Revenue Forecast~ || Market Share~ || Market Share Analysis~ | The Last Word~ || The Last Word—3 Big Predictions~ || Legal Disclaimer~ | Appendix~ || Market Engineering Methodology~ || List of Other Companies in Biomarkers Research, Development, and/or Services~ || List of Exhibits~
List of Charts and Figures 1. Total Cardiac Troponin Diagnostics Market: Market Engineering Measurements, Global, 2016~ 2. Total Cardiac Troponin Diagnostics Market: Revenue Forecast by Region, Global, 2015–2021~ 3. Total Cardiac Troponin Diagnostics Market: Company Market Share Analysis of Top 5 Market Participants, Global, 2016~ 4. Total Cardiac Troponin Diagnostics Market: SWOT Analysis, Global, 2016~ 5. Lab-based Tests Segment: Market Engineering Measurements, Global, 2016~ 6. Lab-based Tests Segment: Company Segment Share Analysis of Top 4 Participants, Global, 2016~ 7. POCT Segment: Market Engineering Measurements, Global, 2016~ 8. POCT Segment: Company Segment Share Analysis of Top 4 Participants, Global, 2016~ 9. Cardiac Troponin Diagnostics Market: New Market Opportunities, US, 2016~ 10. Cardiac Troponin Diagnostics Market: Competitive Structure, US, 2016 ~ 11. Cardiac Troponin Diagnostics Market: Product Analysis, US, 2016~ 12. Cardiac Troponin Diagnostics Market: Key Market Drivers, US, 2017–2021~ 13. Cardiac Troponin Diagnostics Market: Key Market Restraints, US, 2017–2021~ 14. Cardiac Troponin Diagnostics Market: Market Engineering Measurements, US, 2016~ 15. Cardiac Troponin Diagnostics Market: Company Market Share Analysis of Top 7 Participants, US, 2016~ 16. Cardiac Troponin Diagnostics Market: Growth Opportunity Matrix, US, 2016~ 17. Lab-based Tests Segment: Market Engineering Measurements, US, 2016~ 18. Lab-based Tests Segment: Company Market Share Analysis of Top 4 Participants, US, 2016~ 19. POCT Segment: Market Engineering Measurements, US, 2016~ 20. POCT Segment: Company Market Share Analysis of Top 6 Participants, US, 2016~| 1. Total Cardiac Troponin Diagnostics Market: Market Engineering Measurements, Global, 2016 ~ 2. Total Cardiac Troponin Diagnostics Market: Industry Overview, Global, 2016~ 3. Total Cardiac Troponin Diagnostics Market: Market Overview, Global, 2016~ 4. Total Cardiac Troponin Diagnostics Market: Revenue Forecast, Global, 2015–2021~ 5. Total Cardiac Troponins Market: Percent Revenue by Segment, Global, 2016~ 6. Total Cardiac Troponins Market: Percent Revenue Forecast by Segment, Global, 2021~ 7. Total Cardiac Troponin Diagnostics Market: Revenue Forecast by Segment, Global, 2015–2021~ 8. Total Cardiac Troponin Diagnostics Market: Percent Revenue Forecast by Region, Global, 2015–2021~ 9. Total Cardiac Troponin Diagnostics Market: Percent of Revenue by Region, Global, 2016~ 10. Cardiac Troponin Lab-based Test Segment: Percent of Revenue by Region, Global, 2016~ 11. Cardiac Troponin POCT Segment: Percent of Revenue by Region, Global, 2016~ 12. Total Cardiac Troponin Diagnostics Market: Percent Revenue Breakdown, Global, 2016~ 13. Lab-based Tests Segment: Revenue Forecast, Global, 2015–2021~ 14. Lab-based Tests Segment: Percent Revenue Breakdown, Global, 2016~ 15. POCT Segment: Revenue Forecast, Global, 2015–2021~ 16. POCT Segment: Percent Revenue Breakdown, Global, 2016~ 17. Cardiac Troponin Diagnostics Market: Market Engineering Measurements, US, 2016~ 18. Cardiac Troponin Diagnostics Market: Prevalence Rate, US, 2009–2020~ 19. Laboratory Based Tests Segment: Testing Locations, US, 2016~ 20. POCT Based Tests Segment: Testing Locations, US, 2016~ 21. Cardiac Troponin Diagnostics Market: Percent Revenue Breakdown by Region, US, 2016~ 22. Cardiac Troponin Diagnostics Market: Revenue Forecast, US, 2015–2021~ 23. Cardiac Troponin Diagnostics Market: Market Segmentation, US, 2016~ 24. Cardiac Troponin Diagnostics Market: Market Segmentation Forecast, US, 2021~ 25. Cardiac Troponin Diagnostics Market: Revenue Forecast by Segment, US, 2015–2021~ 26. Lab-based Test Segment: Average Price for Lab-based Tests, US, 2015–2021~ 27. Cardiac Troponin Diagnostics Market: Percent Revenue Breakdown, US, 2016~ 28. Cardiac Troponin Diagnostics Market: Percent Revenue Breakdown by Segment, US, 2016~ 29. Lab-based Tests Segment: Revenue Forecast, US, 2015–2021 ~ 30. Lab-based Tests Segment: Percent Revenue Breakdown, US, 2016~ 31. Cardiac Troponin Diagnostics Market: Percent Revenue Breakdown by Segment, US, 2016~ 32. POCT Segment: Revenue Forecast, US, 2015–2021~ 33. POCT Segment: Percent Revenue Breakdown, US, 2016~
Author Sanjeev Kumar
Industries Healthcare
WIP Number P9AF-01-00-00-00
Keyword 1 Cardiac Troponin
Is Prebook No
GPS Codes 9562-B1,9568-B1,9571-B1,9573-B1,9600-B1,9611-B1,9627-B1,99C1-B1,99C6-B1,9A42-B1,9A43-B1,9A44-B1,9A4E-B1,9A50-B1